• Irinotecan Beyond Tumor Killing: The Gut–Liver Axis

  2026-09-08

  Irinotecan research is expanding from tumor-cell cytotoxicity toward chemotherapy-associated gut–liver injury. This article explains how CPT-11 can support integrated colorectal cancer research by connecting topoisomerase I damage, intestinal barrier failure, LPS translocation, and hepatic NET-driven inflammation.

• RepSox and ALK5 Signaling in iPSC Platelet Research

  2026-09-08

  RepSox is a potent and selective ALK5 inhibitor that can help separate TGF-β pathway biology from process optimization in induced pluripotent stem cell research. This article interprets recent platelet-production findings and develops a careful assay framework for testing RepSox without confusing validated evidence with a plausible extension.

• Medroxyprogesterone acetate: Applied Research Workflows

  2026-09-07

  Medroxyprogesterone acetate (MPA) provides a defined steroidal perturbation for endometrial, renal, and neurobiological models. This guide converts its solubility, dose-range, and receptor-context data into practical workflows, while using a recent decidualization study to sharpen assay selection and troubleshooting.

• PD-0332991 Plus Cisplatin in NSCLC Resistance

  2026-09-07

  The reference study investigates whether PD 0332991, a CDK4/6 inhibitor, can enhance cisplatin activity and reverse acquired cisplatin resistance in NSCLC cell models. Its central finding is that combined treatment suppresses proliferation, increases apoptosis and G0/G1 arrest, and modulates the Rb–E2F pathway, providing a mechanistic basis for further preclinical study.

• RNA G-Quadruplexes Modulate TDP-43 Toxicity

  2026-09-05

  Oldani et al. show that RNA G-quadruplexes directly influence TDP-43 aggregation, condensation, intracellular distribution, and toxicity across biochemical and cellular models. The study supports a structure-centered strategy for investigating protein-misfolding diseases while also defining important boundaries between RNA G-quadruplex biology and DNA-targeting ligands.

• Taltirelin acetate: Preclinical Workflow Guide

  2026-09-04

  Taltirelin acetate connects TRHR1 signaling with practical neuroprotection, behavioral, sleep-related, itch, and formulation assays. This guide translates the MPTP and rotenone findings into executable workflows, assay controls, and troubleshooting strategies for translational researchers.

• Gap26 and the Translational Logic of Cx43 Blockade

  2026-09-04

  Gap26 offers a practical way to interrogate connexin 43-dependent ATP, calcium, and inflammatory signaling. This thought-leadership guide connects mechanism, validation strategy, and translational decision-making across vascular and neurobiology research.

• Ridaforolimus and the Next mTOR Research Frontier

  2026-09-03

  Ridaforolimus, also known as Deforolimus or MK-8669, provides a highly potent framework for interrogating mTOR-dependent growth, translation, metabolism, and angiogenic signaling. Combined with machine-learning approaches to senolytic discovery, it supports a more disciplined translational strategy: separate pathway engagement from cell-state selectivity, validate both with orthogonal assays, and advance only the most reproducible biological hypotheses.

• Halazone: From Chloramine Chemistry to Assay Design

  2026-09-03

  Halazone is an antimicrobial sulfonamide derivative with a practical dual identity: a water disinfection agent and an oxidant that alters neuronal sodium-current inactivation. This assay-focused guide explains how concentration, redox conditions, formulation stability, and voltage-clamp design determine interpretable results.

• Mubritinib (TAK 165): Beyond HER2

  2026-09-02

  Mubritinib (TAK 165) is best understood as a mitochondrial complex I probe rather than a conventional HER2 inhibitor. This article explains how that mechanistic reclassification improves AML, PEL, OXPHOS, apoptosis, and translational assay design.

• Anlotinib Hydrochloride: From Assay to Evidence

  2026-09-02

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor whose anti-angiogenic activity can be interpreted more rigorously by connecting receptor pharmacology, endothelial phenotypes, pharmacokinetics, and translational evidence. This article presents an assay-to-evidence framework for cancer research while clarifying what a single case report can—and cannot—establish.

• Isochlorogenic Acid A Targets RIP3 in Cardiac Hypertrophy

  2026-09-01

  A 2026 Cellular Signalling study identifies isochlorogenic acid A as a direct regulator of RIP3 in angiotensin II- and pressure overload-induced cardiac hypertrophy. Its findings connect RIP3 to CaMKII activation independently of MLKL, providing a mechanistic basis for studying maladaptive remodeling and a potential framework for pathway-focused cardiovascular disease research.

• Irinotecan (CPT-11): Mechanism and Research Use

  2026-09-01

  Irinotecan, also called CPT-11, is a carboxylesterase-activated topoisomerase I inhibitor used to model DNA damage, apoptosis, and colorectal cancer biology. Product and peer-reviewed evidence support its use in cell-based cytotoxicity studies, xenograft experiments, and investigations of chemotherapy-associated gut–liver toxicity.

• MPA at the Reproductive Signaling Frontier

  2026-08-31

  Medroxyprogesterone acetate is more than a conventional progestin tool: its progesterone receptor activity, glucocorticoid receptor engagement, and context-dependent epithelial and neural effects make it a strategic probe for translational biology. This article connects MPA research with recent findings on endometrial stromal cell senescence, R-loop resolution, and decidualization while outlining a disciplined path from mechanistic discovery to reproducible model development.

• CDK4/6–BET Synergy in Pancreatic Cancer

  2026-08-31

  Gu et al. show that combining the CDK4/6 inhibitor palbociclib with the BET inhibitor JQ1 can suppress pancreatic ductal adenocarcinoma while counteracting the epithelial-to-mesenchymal transition associated with CDK4/6 inhibition alone. The study links this effect to GSK3β-mediated Wnt/β-catenin signaling and its crosstalk with TGF-β/Smad pathways, providing a mechanistic rationale for combination treatment.

8627 records 1/576 page Next 12345 下5页 Last page